Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 10/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932070 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL29455726 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL24319936 | 0.85 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL12274268 | 0.85 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL18598120 | 0.82 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14042129 | 0.81 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL26844951 | 0.81 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL12184816 | 0.81 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL86695 | 0.81 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL31304970 | 0.81 | CTSK (0.49) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986272-A | Condensed polycyclic compounds, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| CN-1980912-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2007-06-13 | — | — | CN | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | CA1 2481/4885CA2 310/4885CA7 910/4885 |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TFEB, FOXO3, FOXO1 | CA1 4842/4885CA2 4289/4885CA7 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.